[1] Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol, 2015; 1, 505-27. doi:  10.1001/jamaoncol.2015.0735
[2] Zhang X, Sun L. Anaphylatoxin C3a:A potential biomarker for esophageal cancer diagnosis. Mol Clin Oncol, 2018; 2, 315-9. doi:  10.3892/mco.2017.1524/download
[3] Kuninty PR, Schnittert J, Storm G, et al. MicroRNA targeting to modulate tumor microenvironment. Front Oncol, 2016; 6, 3. doi:  10.3389/fonc.2016.00003/full
[4] Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med, 2013; 91, 431-7. doi:  10.1007/s00109-013-1020-6
[5] Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes:current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. BBA-Gen Subjects, 2012; 1820, 940-8. doi:  10.1016/j.bbagen.2012.03.017
[6] Yeung CLA, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun, 2016; 7, 11150. doi:  10.1038/ncomms11150
[7] O'donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nat, 2005; 435, 839-43. doi:  10.1038/nature03677
[8] Yang C, Robbins PD. The Roles of Tumor-Derived Exosomes in Cancer Pathogenesis. CLIN DEV IMMUNOL, 2013; 2011, 842849. https://www.wenkuxiazai.com/doc/dc07a0c64b35eefdc9d333bc.html
[9] Tang MK, Wong AS. Exosomes:Emerging biomarkers and targets for ovarian cancer. Cancer Lett, 2015; 367, 26-33. doi:  10.1016/j.canlet.2015.07.014
[10] Langhe R, Norris L, Saadeh FA, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett, 2015; 356, 628-36. doi:  10.1016/j.canlet.2014.10.010
[11] Hasegawa S, Eguchi H, Nagano H, et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Brit J Cancer, 2014; 111, 1572-80. doi:  10.1038/bjc.2014.454
[12] Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nat, 2015; 523, 177-82. doi:  10.1038/nature14581
[13] Dejima H, Iinuma H, Kanaoka R, et al. Exosomal microRNA in plasma as a noninvasive biomarker for the recurrence of nonsmall cell lung cancer. Oncol Lett, 2017; 13, 1256-63. doi:  10.3892/ol.2017.5569
[14] Zhang H, Mao F, Shen T, et al. Plasma miR145, miR20a, miR21 and miR223 as novel biomarkers for screening earlystage nonsmall cell lung cancer. Oncol Lett, 1899; 13, 669-76.
[15] Li L, Guo Y, Chen Y, et al. The diagnostic efficacy and biological effects of microRNA-29b for colon cancer. Technol Cancer Res T, 2016; 15, 772-9. doi:  10.1177/1533034615604797
[16] Zanutto S, Pizzamiglio S, Ghilotti M, et al. Circulating miR-378 in plasma:a reliable, haemolysis-independent biomarker for colorectal cancer. Brit J Cancer, 2014; 110, 1001-7. doi:  10.1038/bjc.2013.819
[17] Han JG, Jiang YD, Zhang CH, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. J Korean Surg Soc, 2017; 92, 55-66. https://synapse.koreamed.org/Synapse/Data/PDFData/6037ASTR/astr-92-55.pdf
[18] Khan S, Bennit HF, Turay D, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC cancer, 2014; 14, 176. doi:  10.1186/1471-2407-14-176
[19] Zhao Q, Deng S, Wang G, et al. A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget, 2016; 7, 21865-74.
[20] Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol, 2015; 67, 33-41. doi:  10.1016/j.eururo.2014.07.035
[21] Wei W, Leng J, Shao H, et al. MiR-1, a Potential Predictive Biomarker for Recurrence in Prostate Cancer After Radical Prostatectomy. Am J Med Sci, 2017; 353, 315-9. doi:  10.1016/j.amjms.2017.01.006
[22] Liao J, Liu R, Shi YJ, et al. Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. Int J Oncol, 2016; 48, 2567-79. invasive biomarker for the recurrence of nonsmall cell lung cancer. Oncol Lett, 2017; 13, 1256-63. doi:  10.3892/ijo.2016.3453
[23] Liao J, Liu R, Yin L, et al. Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci, 2014; 15, 15530-51. doi:  10.3390/ijms150915530
[24] Mogilyansky E, Rigoutsos I. The miR-17/92 cluster:a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ, 2013; 20, 1603-14. doi:  10.1038/cdd.2013.125
[25] Cao P, Zhou L, Zhang J, et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head & neck, 2013; 35, 720-8.
[26] Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Design, 2013; 19, 1292-300.
[27] Yang J, Han S, Huang W, et al. A meta-analysis of microRNA expression in liver cancer. PLoS One, 2014; 9, e114533. doi:  10.1371/journal.pone.0114533
[28] Thurnherr T, Mah WC, Lei Z, et al. Differentially expressed miRNAs in hepatocellular carcinoma target genes in the genetic information processing and metabolism pathways. Sci Rep, 2016; 6, 20065. doi:  10.1038/srep20065
[29] Li N, Muthusamy S, Liang R, et al. Increased expression of miR-34a and miR-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1. Mech Ageing Dev, 2011; 132, 75-85. doi:  10.1016/j.mad.2010.12.004
[30] Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res, 2008; 14, 2690-5. doi:  10.1158/1078-0432.CCR-07-1731
[31] Armstrong DA, Green BB, Seigne JD, et al. MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer, 2015; 14, 194. doi:  10.1186/s12943-015-0466-2
[32] Pellatt DF, Stevens JR, Wolff RK, et al. Expression profiles of miRNA subsets distinguish human colorectal carcinoma and normal colonic mucosa. Clin Transl Gastroen, 2016; 7, e152. doi:  10.1038/ctg.2016.11
[33] Zhang R, Wang W, Li F, et al. MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. Med Oncol, 2014; 31, 1-8.
[34] Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. P Natl Acad Sci, 2010; 107, 264-9. doi:  10.1073/pnas.0907904107
[35] Kim BH, Hong SW, Kim A, et al. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol, 2013; 107, 505-10. doi:  10.1002/jso.23271
[36] Li Y, Tan W, Neo TW, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci, 2009; 100, 1234-42. doi:  10.1111/cas.2009.100.issue-7
[37] Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer cell, 2008; 13, 272-86. doi:  10.1016/j.ccr.2008.02.013
[38] Guo J, Miao Y, Xiao B, et al. Differential expression of microRNA species in human gastric cancer versus non -tumorous tissues. J Gastroen Hepatol, 2009; 24, 652-7. doi:  10.1111/jgh.2009.24.issue-4
[39] Poliseno L, Salmena L, Riccardi L, et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal, 2010; 3, ra29. http://stke.sciencemag.org/content/3/117/ra29
[40] Fu X, Tian J, Zhang L, et al. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett, 2012; 586, 1279-86. doi:  10.1016/j.febslet.2012.03.006
[41] Xiang Y, Liao XH, Yu CX, et al. MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res, 2017; 357, 135-44. doi:  10.1016/j.yexcr.2017.05.007
[42] Wang SJ, Cao YF, Yang ZQ, et al. MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression. Oncol Lett, 1899; 13, 722-30. https://www.researchgate.net/publication/311481048_MicroRNA-93-5p_increases_multidrug_resistance_in_human_colorectal_carcinoma_cells_by_downregulating_cyclin_dependent_kinase_inhibitor_1A_gene_expression
[43] Brett JO, Renault VM, Rafalski VA, et al. The microRNA cluster miR-106b~25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. Aging (Albany NY), 2011; 3, 108-24.
[44] Wenxi LI, Liang L, Xianghuo HE, et al. The roles of hsa-miR-93 on the hepatocellular carcinoma. Chin J Gastroen Hepatol, 2008; 17, 478-84.
[45] Faraonio R, Salerno P, Passaro F, et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ, 2012; 19, 713-21. doi:  10.1038/cdd.2011.143
[46] Ding Y, Wang XL, Deng HY, et al. Effects of PTEN on esophageal carcinoma cell proliferation and its mechanism. Guangdong Med J, 2014; 35, 3773-7.
[47] Xiao L, Long T, He C. Effects of MAPK signal transduction inhibitors on endometrial carcinoma cells with different PTEN status and its mechanism. Acta Universitatis Medicinalis Anhui, 2014; 49, 613-7.
[48] Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle:a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferat, 2003; 36, 131-49. doi:  10.1046/j.1365-2184.2003.00266.x
[49] Liao XH, Lu DL, Wang N, et al. Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. Febs J, 2014; 281, 927-42. doi:  10.1111/febs.2014.281.issue-3